$328.55
+10.70 (+3.37%)
CSL News30 articles
ASX 200 Flat After Early Gains Fade; Miners Drag, Oil Climbs
The ASX 200 gave up early gains to close nearly flat as surging oil prices and weakness in mining shares offset strength in retail and healthcare.
Healthcare Leads ASX Rotation as CSL Rebounds; Banks Struggle
Healthcare surged 9.2% on the ASX this week, led by CSL's strong results, while banks fell 5.1%. CPI and earnings will test the market next week.
CSL Stock Soars 23% in a Week, Breaking Analyst Price Target
CSL shares jumped 23.3% to A$168.30, beating the average analyst price target of A$163.62, driven by strong cash profit and a positive FY27 outlook.
CSL Soars 25% on FY27 Growth Outlook Despite Statutory Loss
CSL shares surged 25% this week, adding A$16.1 billion in market value, as investors focused on FY27 profit growth guidance despite a statutory loss from impairments.
ASX Weekly Wrap: Healthcare Surge, CPI Test Ahead
Healthcare and materials led a mixed ASX week, while rate-sensitive sectors fell. CPI data and a dense results calendar now set the next test.
CSL Surges Past Analyst Targets After Robust Two-Day Rally
CSL shares soared 23.7% in two sessions, surpassing pre-results analyst targets. The biotech's underlying profit stability and A$1.1 billion buyback fueled investor optimism.
Soybeans Rally on Export Surge; Super Micro Outlook, Oil Spike Highlight Markets
Soybeans ended the week higher on robust export demand, while Super Micro's bullish outlook and a 6% oil surge shaped market sentiment.
Moderna's mRNA Flu Shot Wins FDA Nod, But Sales Loom
Moderna secured FDA approval for its mRNA flu vaccine, but analysts see minimal revenue impact until late 2027, as the company's cash burn continues.
Nifty 50 Retreats as New Closing Rule Rally Fades; Global Markets Mixed
India's Nifty 50 reversed gains tied to a new closing mechanism, while global markets showed mixed signals: Gulf shares advanced, Toyota's profit fell, and a dormant Bitcoin wallet moved $31 million.
CSL Shares Slide 7.4% as HEMGENIX Scale-Up Faces Supply Constraints
CSL shares dropped 7.4% last week as HEMGENIX gene therapy progress remains limited, with supply constraints and revenue concerns weighing on the stock.
CSL Recovers A$16 Billion from Low, Underperforms Plasma Peers
CSL shares have climbed 37% from their low, adding A$16 billion in value, but last week's 0.35% rise trailed plasma sector rivals Grifols and Takeda.
CSL Faces US$650M Revenue Headwinds Ahead of August Earnings Report
CSL Limited (ASX:CSL) disclosed three major revenue headwinds totaling US$650 million, representing 4.3% of FY26 forecast, as it prepares for its August 18 earnings report.
CSL Stock Recovers A$15 Billion, But Revenue Proof Needed
CSL shares have recovered A$15 billion in market value, but investors now require proof of revenue growth following a 34.8% rebound from April lows.
ASX 200 Rallies on Weak Jobs Data, Miners and Reits Lead
Australian shares rallied Thursday as soft jobs data reduced rate hike odds, with the ASX 200 climbing 1.47% led by miners and real estate.
ASX 200 Dips on Bank Weakness, Budget Jitters; Miners Rally on Copper Surge
The S&P/ASX 200 fell 0.36% on Tuesday, dragged lower by banks and tech stocks ahead of the federal budget. Miners rallied as copper hit a record high, with BHP gaining 2.5%.
Australian Shares Tumble on US-Iran Tensions, CSL Plunges 18%
Australian shares opened lower as US-Iran tensions escalate and CSL's 18% plunge drags healthcare down 8%. Energy stocks provide the only bright spot.
ASX 200 Drops to Two-Week Low on Rate Hike Fears, Energy Stocks Rally
The S&P/ASX 200 slipped 0.6% to 8,793.40, its lowest close in two weeks, as financials and miners fell while energy stocks rallied on oil price gains.
ASX 200 Plunges 3.8% Amid Geopolitical Tensions and Rate Fears
Australian equities suffered a sharp 3.8% weekly decline, erasing approximately A$130 billion in market value. The sell-off was driven by escalating Middle East tensions and heightened expectations for RBA rate action.
Pro Medicus Rebounds 9% as Healthcare Tech Recovers from AI Selloff
Pro Medicus shares jumped over 9% on Friday, rebounding from a brutal selloff triggered by AI concerns. First-half revenue grew 28.4% to A$124.8 million, though it fell short of consensus expectations.
Pro Medicus Shares Surge 4.6% Amid Interim Revenue Growth
Pro Medicus shares gained 4.6% on Thursday, closing at A$121.49, despite remaining down 53% over the past year. Interim results showed strong revenue growth and a significant fair value gain from a 4D Medical investment.
CSL Shares Dip Amid Buyback Activity; Eli Lilly Partnership in Focus
CSL shares retreated 0.6% on Friday, ending a two-day advance. The company reported additional buyback activity and confirmed a new licensing agreement with Eli Lilly.
CSL Gains on Lilly Partnership, Buyback Activity Amid Leadership Shift
CSL Limited's stock advanced following a new drug development pact with Eli Lilly and ongoing share repurchases, while the board searches for a permanent CEO.
Wesfarmers Shares Slide Despite Profit Beat as Consumer Spending Concerns Mount
Wesfarmers shares tumbled over 5% despite reporting a half-year profit beat, as management flagged patchy consumer spending and upcoming price investments, overshadowing solid financial results.
CSL Shares Gain on $100M Lilly Kidney Drug Partnership, Buyback Continues
CSL Ltd shares advanced following a $100 million licensing agreement with Eli Lilly for the kidney disease drug clazakizumab. The company also continued its share repurchase program.
CSL Share Buyback Pace in Focus Amid Stock Slide and Leadership Transition
CSL Limited shares declined 0.4% to A$151.56, trailing the broader market, as the company reported additional share repurchases. Investors are monitoring the buyback program's progress ahead of an upcoming dividend payment.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
ASX 200 Ends Flat Amid AI Jitters; CSL Tumbles on CEO Exit
The S&P/ASX 200 closed virtually unchanged, dipping 2.7 points to 8,867.40. Insurance brokers slumped on AI competition fears, while CSL fell 5% after its CEO announced retirement.
CSL CEO Steps Down Ahead of Earnings, Shares Drop Nearly 5%
CSL announced CEO Paul McKenzie's retirement, with Gordon Naylor appointed interim leader. The biotech firm's shares fell 4.98% following the news.
CSL Leadership Transition Weighs on ASX Amid Tech Rebound
CSL shares fell nearly 5% following CEO Paul McKenzie's unexpected retirement, overshadowing a broader market recovery led by technology stocks. The S&P/ASX 200 closed essentially flat at 8,867.4.
CSL CEO Steps Down Ahead of Earnings, Interim Leader Named as Shares Slide
CSL announced CEO Paul McKenzie's retirement, with Gordon Naylor appointed interim chief effective February 11. The leadership change comes one day before the company's half-year results.